Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

REporting recommendations for tumor MARKer prognostic studies (REMARK).

Lisa M McShane1, Douglas G Altman, Willi Sauerbrei

  • 1Biometric Research Branch, DCTD, National Cancer Institute, Room 8126, Executive Plaza North, 6130 Executive Boulevard, Bethesda, MD 20892-7434, USA. lm5h@nih.gov

Breast Cancer Research and Treatment
|August 26, 2006
PubMed
Summary

Clinical utility of cancer tumor markers is limited due to inconsistent study results. Developing reporting guidelines is crucial for transparent evaluation of tumor marker research and clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Population attributable fraction.

BMJ (Clinical research ed.)·2018
Same author

Reporting guidelines for oncology research: helping to maximise the impact of your research.

British journal of cancer·2018
Same author

Updating standards for reporting diagnostic accuracy: the development of STARD 2015.

Research integrity and peer review·2018
Same author

Do declarative titles affect readers' perceptions of research findings? A randomized trial.

Research integrity and peer review·2018
Same author

Choosing important health outcomes for comparative effectiveness research: An updated systematic review and involvement of low and middle income countries.

PloS one·2018
Same author

The INTERGROWTH-21<sup>st</sup> fetal growth standards: toward the global integration of pregnancy and pediatric care.

American journal of obstetrics and gynecology·2018

Area of Science:

  • Oncology
  • Biomarker Research
  • Clinical Diagnostics

Background:

  • Despite extensive research, few tumor markers have proven clinically useful in oncology.
  • Subsequent studies often yield contradictory or inconsistent conclusions regarding tumor marker efficacy.
  • Methodological issues and incomplete reporting hinder the assessment of tumor marker studies.

Purpose of the Study:

  • To address the discrepancies in tumor marker study conclusions.
  • To propose guidelines for the rigorous and transparent reporting of tumor marker studies.
  • To improve the evaluation of tumor marker data and its clinical applicability.

Main Methods:

  • Review of existing challenges in tumor marker research reporting.
  • Proposal of specific guidelines for reporting study design, hypotheses, and patient/specimen characteristics.

Related Experiment Videos

  • Recommendations for assay methods, statistical analysis, data presentation, and discussion content.

    • Main Results:

    • Identified a critical need for standardized reporting in tumor marker research.
    • Developed comprehensive guidelines to enhance the quality and transparency of published studies.
    • Aimed to facilitate better judgment of data usefulness and contextual understanding.

    Conclusions:

    • Standardized reporting guidelines are essential for advancing tumor marker research.
    • Transparent reporting will enable more accurate assessment of tumor marker utility in cancer diagnostics.
    • Implementation of these guidelines will improve the reliability and generalizability of findings.